Market Research Logo

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2015’, provides an overview of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Clostridium Difficile Infections (Clostridium Difficile Associated Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview
Therapeutics Development
Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Overview
Pipeline Products for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Development by Companies
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Development by Companies
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Products under Investigation by Universities/Institutes
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Companies Involved in Therapeutics Development
Absynth Biologics Limited
Actelion Ltd
Adenium Biotech ApS
AIMM Therapeutics B.V.
Akthelia pharmaceuticals ehf
AmpliPhi Biosciences Corporation
Angothera GmbH
Assembly Biosciences, Inc.
AvidBiotics Corp.
C3 Jian, Inc
Daiichi Sankyo Company, Limited
Evec, Inc.
GangaGen Inc.
ImmunoBiology Limited
Immuron Limited
Inovio Pharmaceuticals, Inc.
Intrexon Corporation
MedImmune, LLC
Merck & Co., Inc.
MGB Biopharma Limited
Microbiotix, Inc.
Micropharm Limited
Morphochem AG
Nanotherapeutics, Inc.
Novabiotics Limited
NovoBiotic Pharmaceuticals, LLC
Oragenics, Inc.
Pfizer Inc.
Procarta Biosystems Ltd
Prokarium Limited
Rebiotix Inc.
Sanofi Pasteur SA
Sarum Biosciences Limited
Sequella, Inc.
Seres Therapeutics, Inc.
Shire Plc
Sorrento Therapeutics, Inc.
Stellar Biotechnologies, Inc.
Summit Therapeutics Plc
Synthetic Biologics, Inc.
Valevia UK Limited
Valneva SE
VaxInnate Corporation
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(actoxumab + bezlotoxumab) - Drug Profile
ABCD-01 - Drug Profile
actoxumab - Drug Profile
AKT-10081 - Drug Profile
Antibodies for Enterocolitis - Drug Profile
AP-114 - Drug Profile
AvR2-V10 - Drug Profile
bezlotoxumab - Drug Profile
Biologic for Clostridium Difficile Enteropathy - Drug Profile
Biologic for Clostridium difficile Infections - Drug Profile
C-3CD17 - Drug Profile
cadazolid - Drug Profile
Cdiff snare - Drug Profile
clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
clostridium difficile vaccine - Drug Profile
CRS-3123 - Drug Profile
Drug for Clostridium difficile Infection - Drug Profile
Endolysin - Drug Profile
EV-029104 - Drug Profile
EV-029105A - Drug Profile
fidaxomicin - Drug Profile
GBV-006 - Drug Profile
IMM-529 - Drug Profile
INS-001 - Drug Profile
INX-201 - Drug Profile
MB-101 - Drug Profile
MBX-500 - Drug Profile
MCB-3681 - Drug Profile
MGBBP-3 - Drug Profile
Monoclonal Antibodies for Clostridium difficile - Drug Profile
Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile
Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
MU-1140 - Drug Profile
NP-432 - Drug Profile
OraCAb - Drug Profile
P-2-A - Drug Profile
P-4A - Drug Profile
PF-06425090 - Drug Profile
PolyCAb - Drug Profile
PRO-391 - Drug Profile
ramoplanin - Drug Profile
RBX-2660 - Drug Profile
ridinilazole - Drug Profile
SER-109 - Drug Profile
SER-262 - Drug Profile
Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile
Small Molecules for Clostridium Difficile Infections - Drug Profile
Small Molecules for Clostridium Difficile Infections - Drug Profile
Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile
Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile
SMT-21829 - Drug Profile
SQ-109 - Drug Profile
SQ-641 - Drug Profile
surotomycin - Drug Profile
SYN-004 - Drug Profile
VAL-301 - Drug Profile
VLA-84 - Drug Profile
VP-20621 - Drug Profile
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Recent Pipeline Updates
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2015
Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Absynth Biologics Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Actelion Ltd, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Adenium Biotech ApS, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AIMM Therapeutics B.V., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Akthelia pharmaceuticals ehf, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corporation, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Angothera GmbH, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Assembly Biosciences, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by AvidBiotics Corp., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by C3 Jian, Inc, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Evec, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by GangaGen Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by ImmunoBiology Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Immuron Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Intrexon Corporation, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MedImmune, LLC, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Merck & Co., Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by MGB Biopharma Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Microbiotix, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Micropharm Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Morphochem AG, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Nanotherapeutics, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Novabiotics Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Oragenics, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Pfizer Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Procarta Biosystems Ltd, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Prokarium Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Rebiotix Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sarum Biosciences Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sequella, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Seres Therapeutics, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Shire Plc, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Stellar Biotechnologies, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Synthetic Biologics, Inc., H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Valevia UK Limited, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by Valneva SE, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline by VaxInnate Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics - Recent Pipeline Updates, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Dormant Projects, H2 2015
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), H2 2015
Number of Products under Development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report